2023-05-31 08:47:13 ET
- Panbela Therapeutics ( NASDAQ: PBLA ) has announced that it will implement the previously announced and stockholder approved 1-for-30 reverse split of its common stock.
- The reverse stock split will be effective as of the morning of June 1, 2023, and the company’s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol “PBLA.”
- The CUSIP number for the common stock following the reverse stock split will be 69833W305.
- The reverse stock split is primarily intended to increase the market price per share of the company’s common stock to regain compliance with the continued listing requirements of The Nasdaq.
- PBLA -22.07% premarket to $0.27.
For further details see:
Panbela Therapeutics announces 1-for-30 reverse stock split